http://www.hardmanandco.com/Research/Alliance_June2005.pdf


Web Site : http://www.alliancepharma.co.uk

http://www.hemscott.com/hstoday/Focus_2005/Alliance%20Pharma_1205_2005.htm

Hardmans late June 2005 update

Fair value at 30p

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

Recent buying explained, just been tipped today as a long term buy by uk-analyst.com

Alliance Pharma PLC
10 May 2006
ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Placing to raise 2.5 million

Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has conditionally placed 14,705,883 new ordinary shares of
1p each in the capital of the Company ('Ordinary Shares') at a price of 17p per
share, raising a total of 2.5 million (before expenses) for the Company.
Application has been made to AIM for the new shares to be admitted to trading,
which is expected to commence on 15 May 2006.

The proceeds of the placing will be used for general corporate purposes.

John Dawson, Alliance Pharma's Chief Executive, commented:

'I am delighted by the support of new and existing investors in this
fundraising, the proceeds of which will provide additional finance as the
Company moves closer to the regulatory filing of key pipeline products including
Posidorm for sleep disorders.'

The placing has been undertaken by Numis Securities Limited ('Numis') and is
conditional on the placing agreement between Numis and the Company becoming
unconditional and not being terminated on or before 15 May 2006 (or such later
date as Numis and the Company may agree, being not later than 30 May 2006). The new Ordinary Shares will rank pari passu in all respects with the existing
Ordinary Shares in issue.

For further information:

Alliance Pharma plc +44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications +44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and international pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for
the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

Alliance Pharma PLC 18 May 2006

ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Further expansion of skincare portfolio through bolt-on acquisition
of Caraderm Limited

Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has agreed to acquire Caraderm Limited ('Caraderm'), a
Northern Ireland company whose key asset is Dermamist, a dermatological spray
for dry skin conditions.

Based on 2005 volumes, Dermamist will add annualised sales of 108,000 and adds
a further product to Alliance's growing dermatology portfolio.

Alliance is paying 260,000 in cash for the entire share capital of Caraderm,
under a transaction in which staff will not be transferred to Alliance.

John Dawson, Alliance Pharma's Chief Executive, commented: 'This latest
acquisition delivers a further product to our dermatology portfolio. We gained
critical mass in dermatology earlier this year through the acquisition of the
Hydromol range and we look forward to the continuing success of our skincare
franchise.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

PP

Price is heading in wrong direction...any views?

Free research report to read (its free to register and therefore read it) at

http://www.objectivecapital.co.uk/objectiveresearch.asp?


Just Released August 2006.

Not a lot of interest here, anymore. - and the sp seems to be sliding, - not helped by "further research trials" needed by "EuroMedical" or whatever Authority.
I'm not sure about their China connection either; it might be a bold move, or a can of worms - what do others think? (Presently I don't hold and I'd like to know their cash-position, if anyone acan say for certain).
EDIT 29May: Have bought a few as I suspect this is "the bottom" and I like the way Management is open, etc. (so far).

Sudden 25% rise! ( 10.5p mid.)
Looks like I might break-even - - - and today I looked at their products - quite nice range.....

Maybe this signals a takeover, it's a rapid rise for sure.

Proactive Investors One2One Forums

The directors of Netplay TV Plc (AIM: NPT), Synchronica plc (AIM: SYNC) and Alliance Pharma plc (AIM: APH) will be presenting:

Wednesday the 22nd July 2009

Venue : Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapand wine reception. Details on the presenting companies can be found below.


Register Here : http://www.proactiveinvestors.co.uk/eventregistration.php


These are really good events set in a wonderful location, and are an excellent chance to meet the CEo's of these companies and have an informal chat over free wine and canapafter the formal presentations are complete.

The evenings have a good balance of city professionals, and private investors.

If you have any problems registering or queries please email : action@proactiveinvestors.com


Nearest tube stations are Green Park (5 minutes walk) and Bond Street (7 mins)

Andy,

Did you use to post on the old AOL message board ? if so do you know what as happened to the poster called aknightmight who then changed his name to the french connection and posted on here.

Good news! A Growth equities and Company research report on www.uk-analyst.com talks about APH